PDE5 Inhibitor Β· Evidence Review Β· Blood Flow

Daily Low-Dose Tadalafil & Cognition: What the Evidence Shows

πŸ“„ 13 PubMed citations

Tadalafil is a PDE5 inhibitor: it raises cGMP and relaxes vascular smooth muscle. It is FDA-approved for erectile dysfunction, benign prostatic hyperplasia (BPH) and pulmonary arterial hypertension. Low daily doses (2.5–5 mg) are also discussed for brain blood flow and cognition, cardiovascular health and exercise. This page sets out what the cited research found, at which doses, and what is still untested: the only human trial of tadalafil on cognition cited here, at 20 mg daily for 3 months, found no benefit, and no cited trial has tested cognition at 2.5–5 mg.

PDE5
Inhibitor: raises cGMP, which relaxes vascular smooth muscle
βˆ’2.0
IPSS points vs placebo with 5 mg daily in BPH (PMID 21871706)
17.5hr
Mean half-life in healthy subjects: why once-daily dosing holds steady levels (PMID 16487221)

Still logging injections in your Notes app?

A notes thread can't show a missed day at a glance, because it's a list, not a calendar. A printed log can. Your compounds and dates filled in: injection log, weekly schedule, dated calendar. Free to build and preview; $5/month to unlock printing.

Stacking compounds? Check interactions first →

Build your tracker →

Four Proposed Mechanisms

Four mechanisms are proposed for tadalafil beyond erectile dysfunction. Here is each one, and how far the human data actually go.

🧠

Cerebral Blood Flow

PDE5 mRNA has been detected in mouse and human brain tissue GarcΓ­a-Barroso 2013 (PMID 22776546). When tadalafil inhibits PDE5, cGMP accumulates β†’ smooth muscle relaxation β†’ vasodilation. Human brain blood flow results are mixed: a single 20 mg dose gave a non-significant rise in subcortical blood flow in older adults with small vessel disease PASTIS 2022 (PMID 35135037), while 3 months of 20 mg daily raised whole-brain blood flow by 3.3 ml/100 g/min over placebo (from a baseline of 25.4) in a small-vessel-disease MRI sub-study ETLAS-2 2026 (PMID 42643719). No trial cited here has tested brain blood flow at 2.5–5 mg.

⚑

Stimulant Counterbalance (Untested)

Some biohackers pair tadalafil with modafinil, caffeine or amphetamines on the theory that a vasodilator offsets stimulant-related vasoconstriction. That is a hypothesis, not a finding: none of the research cited on this page tested tadalafil with any stimulant, so there is no evidence on whether the combination works or is safe. Tadalafil lowers blood pressure Curr Vasc Pharmacol 2022 (PMID 36043781), so any combination is one to clear with a physician first.

❀️

Cardiovascular Effects

Tadalafil is FDA-approved as Adcirca for pulmonary arterial hypertension, but at 40 mg once daily: in the PHIRST trial only the 40 mg dose significantly improved 6-minute walk distance, and the 2.5 mg arm did not Circulation 2009 (PMID 19470885). On endothelial function the cited trials are null: low-dose tadalafil matched placebo on flow-mediated dilation in men with ED Sex Med 2019 (PMID 30638829). A 2.5–5 mg daily dose has not been shown to improve endothelial function.

πŸ”¬

Neuroprotection

In a mouse model of Alzheimer's disease, GarcΓ­a-Barroso et al. showed tadalafil crosses the blood–brain barrier, and 10 weeks of treatment improved water-maze performance and reduced hippocampal tau phosphorylation without changing amyloid burden Neuropharmacology 2013 (PMID 22776546). Human data are thin. The often-cited Shim et al. 2014 daily low-dose trial in ED patients tested udenafil, a different PDE5 inhibitor, not tadalafil Int J Impot Res 2014 (PMID 24285284). In the ETLAS-2 trial, 3 months of tadalafil 20 mg daily did not improve cognition versus placebo in small vessel disease Cereb Circ Cogn Behav 2025 (PMID 41332889).

What the Studies Show

The cognitive research on tadalafil is mostly preclinical, and the few human trials so far are small and mostly null. Here's an honest breakdown of what we know.

πŸ“š
Research Transparency Note: Most cognitive data come from animal models. The human trials are small: one found higher whole-brain blood flow after 3 months of 20 mg daily in small vessel disease (PMID 42643719) but no cognitive benefit in the same trial (PMID 41332889). The endothelial-function (FMD) trials cited on this page found no difference from placebo (PMID 30638829, PMID 36043781). Large human RCTs of tadalafil for cognitive enhancement do not yet exist.
Cerebrovascular Effects: Evidence Strength
PDE5 mRNA in brain tissue (mouse + human)
Detected
Brain blood flow increase (human, 20 mg)
Mixed: 1 positive, 1 null
Endothelial function (FMD) vs placebo
Not shown
Memory improvement: mouse Alzheimer's model
Preclinical
Cognitive benefit in a human RCT (tadalafil)
Not shown
Cognitive enhancement in healthy humans (RCT)
Lacking
FDA-Approved Applications: Evidence Base
Erectile dysfunction (Cialis)
FDA approved
Benign prostatic hyperplasia
FDA approved
Pulmonary arterial hypertension (Adcirca)
FDA approved

Doses Used in the Research

The human tadalafil trials cited on this page used doses from 2.5 mg (the lowest PHIRST arm) to 40 mg daily. The brain blood flow and cognition trials used 20 mg (a single dose in PASTIS, daily for 3 months in ETLAS-2); 5 mg daily is the BPH dose. This section describes what was studied, not a dosing instruction.

Daily Low Dose
2.5–5mg
Daily, continuous use. Once-daily dosing reaches steady state by about day 5 (PMID 16487221). 5 mg daily is the dose tested in the BPH trials (PMID 21871706); it has not been tested for cognition.
Cognition & Brain Blood Flow Trials
20mg daily
The ETLAS-2 trial in small vessel disease gave 20 mg daily for 3 months: whole-brain blood flow rose versus placebo (PMID 42643719), but cognition did not improve (PMID 41332889).
On-Demand ED Dosing
10–20mg
On-demand dosing. Higher doses, taken less often.
Half-Life
~17.5 hours
Mean half-life in healthy subjects (5th–95th percentile 11.5–29.6 h), with about 1.6-fold accumulation on once-daily dosing; its systemic clearance is low relative to other PDE5 inhibitors (PMID 16487221). This long half-life is what makes once-daily dosing practical.
Timing & Food
Flexible
Food has negligible effect on absorption and time of dosing does not substantially change exposure (PMID 16487221). There is no interaction data for tadalafil with modafinil or other stimulants in the research cited here; clear any combination with a physician.
⚠️
Critical Contraindication: Tadalafil is absolutely contraindicated with nitrate medications (nitroglycerin, isosorbide, amyl nitrite). The combination can cause severe hypotension. If you take any nitrates for any reason, do not take tadalafil.
🩺
Medical Supervision Required: Tadalafil is a prescription drug. Get bloodwork first. Discuss with a physician. This page documents the research, not a personal recommendation. PDE5 inhibitors can interact with other medications and conditions.

Approved vs. Off-Label Uses

Tadalafil has three FDA-approved uses. The off-label uses below are proposed, not established; the evidence for each is noted.

πŸ’Š
Erectile Dysfunction
The well-known indication. This is why most men get it prescribed.
FDA Approved
🫁
Pulmonary Arterial Hypertension
FDA-approved as Adcirca. In the PHIRST trial, 40 mg once daily improved 6-minute walk distance and reduced clinical worsening (PMID 19470885).
FDA Approved
πŸ«€
Benign Prostatic Hyperplasia
Approved for lower urinary tract symptoms from BPH. Smooth muscle relaxation in the prostate and bladder neck.
FDA Approved
🧠
Cognitive Enhancement
Proposed via brain blood flow and animal-model neuroprotection. The biohacker community's primary interest, but a 3-month human RCT found no cognitive benefit (PMID 41332889).
Off-Label
πŸƒ
Exercise Performance
Proposed via greater blood flow to working muscle. The clear exercise gain in the research cited here is in pulmonary arterial hypertension at 40 mg daily (PMID 19470885); none of the cited trials studied healthy athletes.
Off-Label

Tadalafil vs. Sildenafil for Daily Use

For once-daily use, the differences the cited sources document are pharmacokinetic. Nothing in this table is evidence of a cognitive effect for either drug.

Property Tadalafil (Cialis) Sildenafil (Viagra)
Half-Life~17.5 hours (PMID 16487221)Not reported in the sources cited here
Daily Dosing ViabilityYes, 2.5–5mg dailyNot covered by the sources cited here
Food InteractionNegligible (PMID 16487221)Food slows absorption, delaying peak by ~1 h (PMID 11879254)
Once-Daily Low-Dose RCT DataYes: 5mg daily in BPH (PMID 21871706)Not covered by the sources cited here
FDA Approval for PAHYes (as Adcirca)Yes (as Revatio)

Cardiovascular & Endothelial Health

Tadalafil's vascular effects have also been studied outside the brain. The strongest human evidence is in pulmonary arterial hypertension, at 40 mg once daily, well above 2.5–5 mg. Peripheral endothelial-function results are mostly null.

πŸ«€
The PAH proof-of-concept: In the landmark PHIRST randomized trial, tadalafil 40 mg daily increased the 6-minute walk distance by a placebo-corrected 33 metres in patients with pulmonary arterial hypertension (44 m in those not on background bosentan). The effect was dose-dependent and only the 40 mg dose reached statistical significance; the 2.5 mg arm did not. That is human evidence that tadalafil at the PAH dose improves exercise capacity in PAH, not evidence for a 2.5–5 mg dose. GaliΓ¨ et al., Circulation 2009 (PMID 19470885).
Vascular Effects: What Human Studies Actually Show
Exercise capacity in PAH (40 mg daily)
RCT-confirmed
Arterial stiffness / pulse-wave velocity (single 20 mg dose)
Acute only
Circulating endothelial progenitor cells (EPCs)
One small study
Flow-mediated dilation (FMD) improvement
No benefit vs placebo
πŸ“‰
Arterial Stiffness
A placebo-controlled trial in grade-1 obesity found a single 20 mg dose lowered systolic blood pressure and brachial-ankle pulse-wave velocity (a marker of arterial stiffness), though it did not change flow-mediated dilation in that cohort. Curr Vasc Pharmacol 2022 (PMID 36043781).
🧫
Endothelial Repair Cells
In 30 men with erectile dysfunction and metabolic syndrome, three months of on-demand tadalafil 20 mg significantly increased circulating endothelial progenitor cells in both responders and poor responders; the author reads this as a preserved bone-marrow repair response. Int Angiol 2011 (PMID 21804479).
βš–οΈ
Honest Caveat: FMD
A double-blind RCT of low-dose tadalafil in ED patients found flow-mediated dilation improved about equally on tadalafil and placebo (mean change 2.4 vs 2.8 points, P=.528), so tadalafil did not outperform placebo on FMD Sex Med 2019 (PMID 30638829), and a single 20 mg dose did not change FMD in grade-1 obesity (PMID 36043781). Outside pulmonary arterial hypertension (40 mg daily), the positive vascular findings cited on this page all came at 20 mg: lower blood pressure and pulse-wave velocity after a single dose (PMID 36043781), more circulating endothelial progenitor cells after 3 months on demand (PMID 21804479), and higher whole-brain blood flow after 3 months daily (PMID 42643719). None was tested at 2.5–5 mg.
⚠️
Not a substitute for cardiac care: Tadalafil lowers blood pressure (PMID 36043781). It must never be combined with nitrate medications, and combining it with alpha-blockers calls for caution and a physician's review. None of the data above means tadalafil should replace established cardiovascular treatment. It is not a cardioprotective drug with hard-outcome trials behind it.

Exercise Performance & Recovery

If vasodilation increases oxygen and nutrient delivery to working tissue, the obvious question is whether that translates to exercise. The honest answer: clearly in pulmonary arterial hypertension at 40 mg; the research cited here includes no trials in healthy athletes.

🫁

Exercise Capacity in PAH

The strongest performance signal comes from disease populations. In PHIRST, tadalafil 40 mg once daily improved the 6-minute walk distance by a placebo-corrected 33 metres in pulmonary arterial hypertension, a real, measured increase in exercise tolerance. Only the 40 mg dose reached statistical significance. Circulation 2009 (PMID 19470885).

πŸ’¨

Muscle Oxygen Delivery

The rationale some athletes cite is that a vasodilator could raise blood flow to working muscle. None of the research cited on this page measured muscle blood flow or exercise performance in healthy people, so for them this remains a hypothesis.

♻️

Recovery Rationale

Greater perfusion theoretically aids nutrient clearance and delivery during recovery, and the ~17.5-hour half-life (PMID 16487221) means once-daily dosing keeps levels steady across back-to-back training days. The recovery angle is a hypothesis, not established by controlled human recovery trials.

πŸƒ
Reality check for healthy athletes: The only clear exercise gain in the research cited here is in people with pulmonary arterial hypertension, at 40 mg daily (PMID 19470885). None of the cited trials tested performance in people with normal circulation, so tadalafil is not a proven ergogenic aid.

Benign Prostatic Hyperplasia (BPH)

This is not off-label or speculative: tadalafil 5 mg once daily is FDA-approved for the signs and symptoms of benign prostatic hyperplasia. It is the clearest randomized evidence for a daily 5 mg dose among the studies cited here, and that evidence is for urinary symptoms, not cognition.

πŸ“Š
Randomized evidence: In an international, double-blind, placebo-controlled trial, tadalafil 5 mg once daily produced a clinically meaningful reduction in total IPSS (International Prostate Symptom Score), roughly a 2.0-point greater improvement than placebo (p=0.004), with improvement apparent at one week and statistically significant by week four. Porst et al., Eur Urol 2011 (PMID 21871706).
BPH / LUTS: Evidence Strength
IPSS symptom improvement vs placebo (daily 5 mg)
RCT-confirmed
Similar to tamsulosin, each vs placebo
Not powered head-to-head
Added benefit: treats LUTS + ED together
Distinct advantage
Effect on urinary flow rate (Qmax)
Modest / variable
βš–οΈ
Vs. the standard of care: An international randomized trial compared tadalafil and the alpha-blocker tamsulosin each against placebo and found numerically similar improvements in LUTS suggestive of BPH (IPSS βˆ’2.1 vs placebo for tadalafil, p=0.001; βˆ’1.5 for tamsulosin, p=0.023), but only tadalafil also improved erectile function. The trial was not powered to compare the two drugs directly. For a man with both LUTS and ED, one daily 5 mg tablet addresses both. Oelke et al., Eur Urol 2012 (PMID 22297243).
🩺
What it doesn't do: Tadalafil improves the symptoms of BPH (urgency, frequency, weak stream) but has only a modest, variable effect on peak urinary flow rate and does not shrink the prostate the way 5-alpha-reductase inhibitors (finasteride/dutasteride) do. It treats how you feel, not prostate size. New or worsening urinary symptoms warrant a urology workup to rule out other causes.

What We Know & What We Don't

Well-Supported
  • Tadalafil inhibits PDE5 and increases cGMP, the final mediator of the nitric oxide pathway (PMID 19470885)
  • PDE5 mRNA is present in mouse and human brain; tadalafil crosses the blood–brain barrier in mice (PMID 22776546)
  • ~17.5-hour mean half-life; once-daily dosing reaches steady state by day 5 (PMID 16487221)
  • FDA-approved for BPH β€” daily 5mg cuts IPSS ~2 points vs placebo (PMID 21871706)
  • FDA-approved for PAH β€” 40mg daily added +33m 6-min walk in PHIRST; the 2.5mg arm was not significant (PMID 19470885)
  • 3 months of 20mg daily raised whole-brain blood flow vs placebo in small vessel disease (PMID 42643719)
  • Mouse Alzheimer's model: 10 weeks of tadalafil improved water-maze memory and lowered tau phosphorylation (PMID 22776546)
  • A single 20mg dose lowered blood pressure and pulse-wave velocity in grade-1 obesity (acute effect; PMID 36043781)
Still Needed
  • Large-scale human RCTs for cognitive enhancement; a 3-month RCT at 20mg daily found no cognitive difference vs placebo (PMID 41332889)
  • Long-term safety data for daily use beyond 5 years
  • Any brain blood flow or cognitive data at 2.5–5mg daily
  • Any interaction or efficacy data for tadalafil combined with modafinil, other stimulants or nootropics
  • Head-to-head cognitive data vs. sildenafil at equivalent doses
  • Performance data in healthy young adults (most studies in older/patient populations)
  • Any endothelial-function (FMD) benefit β€” the cited trials found none vs placebo (PMID 30638829, 36043781)
  • Placebo-controlled confirmation of the endothelial progenitor cell rise seen with 3 months of on-demand 20mg in one small before-and-after study of 30 men with ED + metabolic syndrome, no placebo arm (PMID 21804479)
  • Proven ergogenic effect in healthy, well-trained athletes (signal is in disease populations)
  • Effect on urinary flow rate (Qmax) in BPH is modest and variable β€” it eases symptoms, not prostate size

Monitoring tools, plus two nitric-oxide-related supplements. None were tested with tadalafil in the research cited here; ask a physician before combining anything with a PDE5 inhibitor.

πŸ§ͺ Tadalafil for Laboratory Research Human use of tadalafil is prescription-only (Cialis, Adcirca), and the doses on this page describe what clinical trials studied, not instructions. Separately, Swiss Chems lists tadalafil as a research chemical for laboratory use. View tadalafil at Swiss Chems β€” sold for research purposes only, not for human consumption, and not a substitute for a prescription and a physician's care.

Affiliate links support HighPeptides at no extra cost.

πŸ“š

Want the Complete Protocol Guide?

Dosing schedules, interaction warnings, and cycle protocols for 20+ compounds, all in one place.


Get the Guide: $19 (normally $29) →
The Peptide Buyer’s Playbook ($19)
Medical Disclaimer
This page is for educational and informational purposes only. It is not medical advice. Tadalafil is a prescription drug (FDA-approved as Cialis and Adcirca). Off-label uses discussed here are not approved by the FDA for those indications. Always consult with a qualified healthcare provider before starting any medication. Data sourced from published peer-reviewed research; see citations throughout. Individual results vary. HighPeptides does not sell tadalafil.
📘

Get the Free 2026 Peptide Protocol Stack

Twelve compounds across four pillars: metabolic, tissue repair, longevity, cognitive. Citations included, formatted to print. Sent straight to your inbox.